A PYMNTS Company

EU: Commission updates on pharma market review

By  |  January 31, 2013

In a press release it has been announced that the European Commission has concluded its look into Europe’s pharmaceutical industry and has decided to take action against pharmaceutical companies in three major cases, issuing the companies statements of objections. The inquiry into the sector ran from 2008-2009. In its search, the Commission found weaker-than-expected competition contributed by generic producers, attributing the find to pay-for-delay transactions, as well as competition problems by market dominators who look to shut out the generic competitors from the market. Following these findings, the Commission sent statements of objections to more than 14 companies in two cases of possible competition infringement through “anticompetitive agreements and, in part, unilateral practices.”

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    Full Content: European Commission

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.